uniQure Announces Meeting With UK MHRA And Plans To Submit Marketing Authorization Application For AMT-130 For The Treatment Of Huntington's Disease In Q3 2026
During the meeting, the Company and MHRA discussed the data package and manufacturing requirements to support a MAA submission for AMT-130. Following these discussions, the Company expects to submit a MAA based on the
04/30/2026